145 related articles for article (PubMed ID: 36682089)
1. EMACO for treatment of gestational trophoblastic neoplasia: A multinational multicenter study.
Jareemit N; Therasakvichya S; Freitas F; Paiva G; Ramírez LAC; Berkowitz RS; Horowitz NS; Maestá I; Fülöp V; Braga A; Elias KM
Gynecol Oncol; 2023 Mar; 170():114-122. PubMed ID: 36682089
[TBL] [Abstract][Full Text] [Related]
2. EMA vs EMACO in the treatment of gestational trophoblastic neoplasia.
Jareemit N; Horowitz NS; Goldstein DP; Berkowitz RS; Elias KM
Gynecol Oncol; 2020 Jul; 158(1):99-104. PubMed ID: 32404247
[TBL] [Abstract][Full Text] [Related]
3. [EMA/CO regimen for chemotherapy 24 patients with ultra high-risk gestational trophoblastic neoplasia].
Shen T; Chen LL; Qin JL; Wang XY; Cheng XD; Xie X; Lyu WG
Zhonghua Fu Chan Ke Za Zhi; 2018 Jun; 53(6):371-376. PubMed ID: 29961278
[No Abstract] [Full Text] [Related]
4. Treatment of high-risk gestational trophoblastic neoplasia with etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine chemotherapy.
Escobar PF; Lurain JR; Singh DK; Bozorgi K; Fishman DA
Gynecol Oncol; 2003 Dec; 91(3):552-7. PubMed ID: 14675675
[TBL] [Abstract][Full Text] [Related]
5. Relapsed or refractory gestational trophoblastic neoplasia treated with the etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EP-EMA) regimen.
Mao Y; Wan X; Lv W; Xie X
Int J Gynaecol Obstet; 2007 Jul; 98(1):44-7. PubMed ID: 17481633
[TBL] [Abstract][Full Text] [Related]
6. Importance of salvage therapy in the management of high-risk gestational trophoblastic neoplasia.
Lurain JR; Schink JC
J Reprod Med; 2012; 57(5-6):219-24. PubMed ID: 22696816
[TBL] [Abstract][Full Text] [Related]
7. Cyclophosphamide, hydroxyurea, actinomycin D, methotrexate, and vincristine in the treatment of gestational trophoblastic neoplasia.
Chu MM; Ma Y; Tse KY; Chan KK; Ngan HY
Int J Gynecol Cancer; 2015 Mar; 25(3):498-503. PubMed ID: 25628108
[TBL] [Abstract][Full Text] [Related]
8. M-EA (methotrexate, etoposide, dactinomycin) and EMA-CO (methotrexate, etoposide, dactinomycin / cyclophosphamide, vincristine) regimens as first-line treatment of high-risk gestational trophoblastic neoplasia.
Singh K; Gillett S; Ireson J; Hills A; Tidy JA; Coleman RE; Hancock BW; Winter MC
Int J Cancer; 2021 May; 148(9):2335-2344. PubMed ID: 33210289
[TBL] [Abstract][Full Text] [Related]
9. Salvage chemotherapy for gestational trophoblastic neoplasia: Utility or futility?
Essel KG; Bruegl A; Gershenson DM; Ramondetta LM; Naumann RW; Brown J
Gynecol Oncol; 2017 Jul; 146(1):74-80. PubMed ID: 28473205
[TBL] [Abstract][Full Text] [Related]
10. Results with Floxuridine, Actinomycin D, Etoposide, and Vincristine in Gestational Trophoblastic Neoplasias with International Federation of Gynecology and Obstetrics Scores ≥5.
Li Y; Kong Y; Wan X; Feng F; Ren T; Zhao J; Yang J; Xiang Y
Oncologist; 2021 Dec; 26(12):e2209-e2216. PubMed ID: 34396643
[TBL] [Abstract][Full Text] [Related]
11. Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors.
Newlands ES; Mulholland PJ; Holden L; Seckl MJ; Rustin GJ
J Clin Oncol; 2000 Feb; 18(4):854-9. PubMed ID: 10673528
[TBL] [Abstract][Full Text] [Related]
12. The added value of hysterectomy in the management of gestational trophoblastic neoplasia.
Eysbouts YK; Massuger LFAG; IntHout J; Lok CAR; Sweep FCGJ; Ottevanger PB
Gynecol Oncol; 2017 Jun; 145(3):536-542. PubMed ID: 28390821
[TBL] [Abstract][Full Text] [Related]
13. Comparing cisplatin-based combination chemotherapy with EMA/CO chemotherapy for the treatment of high risk gestational trophoblastic neoplasia.
Lybol C; Thomas CM; Blanken EA; Sweep FC; Verheijen RH; Westermann AM; Boere IA; Reyners AK; Massuger LF; van Hoesel RQ; Ottevanger PB
Eur J Cancer; 2013 Mar; 49(4):860-7. PubMed ID: 23099004
[TBL] [Abstract][Full Text] [Related]
14. Response to chemotherapy in overweight/obese patients with low-risk gestational trophoblastic neoplasia.
Maestá I; Horowitz NS; Goldstein DP; Bernstein MR; Ramírez LA; Moulder J; Berkowitz RS
Int J Gynecol Cancer; 2015 May; 25(4):734-40. PubMed ID: 25675037
[TBL] [Abstract][Full Text] [Related]
15. Predictors for single-agent resistance in FIGO score 5 or 6 gestational trophoblastic neoplasia: a multicentre, retrospective, cohort study.
Braga A; Paiva G; Ghorani E; Freitas F; Velarde LGC; Kaur B; Unsworth N; Lozano-Kuehne J; Dos Santos Esteves APV; Rezende Filho J; Amim J; Aguiar X; Sarwar N; Elias KM; Horowitz NS; Berkowitz RS; Seckl MJ
Lancet Oncol; 2021 Aug; 22(8):1188-1198. PubMed ID: 34181884
[TBL] [Abstract][Full Text] [Related]
16. Combination chemotherapy for primary treatment of high-risk gestational trophoblastic tumour.
Deng L; Zhang J; Wu T; Lawrie TA
Cochrane Database Syst Rev; 2013 Jan; 2013(1):CD005196. PubMed ID: 23440800
[TBL] [Abstract][Full Text] [Related]
17. Salvage combination chemotherapy with floxuridine, dactinomycin, etoposide, and vincristine (FAEV) for patients with relapsed/chemoresistant gestational trophoblastic neoplasia.
Feng F; Xiang Y; Wan X; Geng S; Wang T
Ann Oncol; 2011 Jul; 22(7):1588-1594. PubMed ID: 21239399
[TBL] [Abstract][Full Text] [Related]
18. Clinical epidemiology and management of gestational trophoblastic neoplasia in Hungary in the past 34 years.
Fülöp V; Szigetvári I; Szepesi J; Végh G; Singh M; Berkowitz RS
J Reprod Med; 2012; 57(7-8):310-8. PubMed ID: 22838247
[TBL] [Abstract][Full Text] [Related]
19. Conservative Chemotherapy in Gestational Trophoblastic Disease: Experience With Etoposide, Methotrexate, and Dactinomycin Chemotherapy.
Byun SW; Park TC; Bae SN
Int J Gynecol Cancer; 2016 May; 26(4):790-5. PubMed ID: 27057813
[TBL] [Abstract][Full Text] [Related]
20. Secondary chemotherapy for high-risk gestational trophoblastic neoplasia.
Lurain JR; Nejad B
Gynecol Oncol; 2005 May; 97(2):618-23. PubMed ID: 15863169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]